Endostar (recombinant human endostatin)

P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital

This work demonstrated for the first time that Endostar enhanced the antitumor efficacy of Osimertinib, offering a potential therapeutic approach for patients harboring triple mutations.

P3, N=290, Active, not recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Feb 2025

P1/2, N=10, Completed, Shanghai 6th People's Hospital | Recruiting --> Completed | Trial completion date: Oct 2025 --> Jul 2025 | Trial primary completion date: Sep 2025 --> Apr 2025

The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39). In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation.

P2, N=59, Recruiting, Fujian Provincial Hospital; Fujian Provincial Hospital

P2, N=52, Completed, Fudan University | Unknown status --> Completed | N=76 --> 52

The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications.

P=N/A, N=290, Recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

It is important because only in combination with MHC class I on target cells can tumor antigenic peptides be recognized by CD8+ CTLs which destroy target cells. However, MHC class I is frequently deficient in cancer cells.

P2, N=58, Recruiting, Fudan University

P1/2, N=10, Recruiting, Shanghai 6th People's Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Oct 2025 | Initiation date: Aug 2024 --> Dec 2024 | Trial primary completion date: Apr 2025 --> Sep 2025